Tue, Mar
10 New Articles

Top Stories

Grid List

Pharnext SA , a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases announced a research and development (R&D) agreement with Galapagos NV.

Titan Pharmaceuticals, Inc ,a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform announced that the U.S. FDA has completed its initial review of the ropinirole implant Investigational New Drug Application (IND) and has requested that Titan hold the initiation of the clinical study pending submission of the requested information and the agency's 30-day review. 

Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody.

Selvita , a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML).

LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema. 

Inovio Pharmaceuticals, Inc. announced that Dr. David B. Weiner, Inovio’s co-founder, presented positive clinical data on Inovio’s DNA-based vaccines against MERS (GLS-5300) and Zika (GLS-5700) at the Coalition for Epidemic Preparedness Innovation (CEPI)’s 1st Scientific Meeting on “Vaccines Against Emerging Infections - A Global Insurance” in Paris, France.

Charles River Laboratories International, Inc. , a leading early-stage contract research organization announced that it has extended its longstanding, strategic, integrated drug discovery partnership with Chiesi Farmaceutici SpA in the field of respiratory disease.

Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to update shareholders on continuing efforts to develop the oral dosing of Kevetrin.

Johnson Matthey, a global specialty chemicals company and provider of advanced process technologies, and Rennovia Inc., a privately held company that develops novel catalysts and processes for the cost advantaged production of chemical products from renewable feedstocks.

Mettler-Toledo, a market leader in product inspection technology, will present a comprehensive range of solutions and upgradesat interpack 2017 (www.mt.com/interpack17) for both the food and pharmaceutical sectors, as well as providing a wealth of technical knowledge via its experts at the stand.

Life science researchers working across many applications can now benefit from the first-ever web-based pipetting application, developed to enable seamless connectivity with electronic pipettes for optimized performance and safe, efficient and rapid sharing of protocols.

Fluorescing UV inks offer a number of advantages, including high print quality, improved durability and enhanced productivity.

Upcoming Events

Market Movers

Rogers Corporation Common Stock

NYQ : ROG - 27 Mar, 4:02pm
+0.67 (+0.80%) After Hours:
Open 82.22 Mktcap 1.52B
High 84.44 52wk Hight 90.45
Low 81.72 52wk Low 51.98
Vol 58434 Avg Vol 103337
Eps 4.44 P/e 31.75
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 27 Mar, 4:00pm
+0.01 (+0.16%) After Hours:
Open 6.11 Mktcap 89.53B
High 6.15 52wk Hight 6.20
Low 6.09 52wk Low 3.60
Vol 4.73M Avg Vol 5.08M
Eps 0.49 P/e 14.05
Currency: USD

Merck & Company, Inc. Common St

NYQ : MRK - 27 Mar, 4:00pm
+0.01 (+0.02%) After Hours:
Open 62.92 Mktcap 173.49B
High 63.41 52wk Hight 66.80
Low 62.81 52wk Low 52.44
Vol 8.02M Avg Vol 10.71M
Eps 3.81 P/e 44.82
Currency: USD

Johnson & Johnson Common Stock

NYQ : JNJ - 27 Mar, 4:00pm
+0.32 (+0.26%) After Hours:
Open 125.16 Mktcap 341.34B
High 126.14 52wk Hight 129.00
Low 125.15 52wk Low 107.69
Vol 5.00M Avg Vol 7.08M
Eps 7.04 P/e 21.21
Currency: USD

Pfizer, Inc. Common Stock

NYQ : PFE - 27 Mar, 4:00pm
+0.18 (+0.53%) After Hours:
Open 33.74 Mktcap 203.43B
High 34.31 52wk Hight 37.39
Low 33.74 52wk Low 29.41
Vol 17.89M Avg Vol 24.99M
Eps 2.55 P/e 29.14
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 27 Mar, 8:00pm
-0.11 (-0.77%) After Hours:
Open 14.77 Mktcap
High 14.79 52wk Hight 16.29
Low 14.69 52wk Low 12.60
Vol 4218 Avg Vol 12815
Eps P/e
Currency: USD
Sign up via our free email subscription service to receive notifications when new information is available.

Ferring Pharmaceuticals announced an agreement with Apricus Biosciences, Inc, granting Ferring global assets and rights, excluding the U.S., related to Apricus’ Vitaros.

Thermo Fisher Scientific Inc, the world leader in serving science announced that it has acquired Core Informatics, which provides a leading cloud-based platform supporting scientific data management.

ICON plc a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US FDA to validate three PRO instruments that will measure clinical endpoints in antibacterial drug trials.

Regenerative and cell-based therapies have only recently begun to deliver on the promise they have portended for years, creating opportunities to positively impact patient outcomes and professional success.

Type 2 diabetes awareness is rising in the United States. Public and private health leaders are now offering screenings and patient education sites that discuss “prediabetes,” to detect and treat the disease in its earliest stages.

Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers.

TraceLink Inc, the World’s Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace.

TV spot showcases the science behind the ultimate breathability and comfort of DAILIES TOTAL1® contact lenses

Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc announced that the U.S. FDA granted approval for Basaglar 100 units/mL. BASAGLAR is a long-acting insulin with an identical amino acid sequence to Lantus®, another U-100 insulin glargine.